32 related articles for article (PubMed ID: 31820498)
1. Plasma miR-125a and miR-125b in sepsis: Correlation with disease risk, inflammation, severity, and prognosis.
Zhao D; Li S; Cui J; Wang L; Ma X; Li Y
J Clin Lab Anal; 2020 Feb; 34(2):e23036. PubMed ID: 32077163
[TBL] [Abstract][Full Text] [Related]
2. Blood MALT1 expression could help predict treatment outcomes in psoriasis patients, especially in those receiving biologics.
Liu Q; Zhang Y; Xu B; Jin X; Yang T; Fan L
Immun Inflamm Dis; 2024 Apr; 12(4):e1235. PubMed ID: 38578002
[TBL] [Abstract][Full Text] [Related]
3. Serum miRNA profiling identified miRNAs associated with disease severity in psoriasis.
Ganguly T; Laha S; Senapati S; Chatterjee G; Chatterjee R
Exp Dermatol; 2024 Jan; 33(1):e14973. PubMed ID: 37926911
[TBL] [Abstract][Full Text] [Related]
4. Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review.
Puig L; Fernández-Freire LR; Burgos-Pol R; Gomez I; Peral C; Gomez S; Rebollo Laserna FJ
Dermatol Ther (Heidelb); 2019 Sep; 9(3):479-496. PubMed ID: 31062222
[TBL] [Abstract][Full Text] [Related]
5. Association between several immune response-related genes and the effectiveness of biological treatments in patients with moderate-to-severe psoriasis.
Loras A; Gil-Barrachina M; Hernando B; Perez-Pastor G; Martinez-Domenech A; Mahiques L; Pitarch G; Valcuende-Cavero F; Ballester-Sanchez R; Marques-Torrejon MA; Martinez-Cadenas C
Exp Dermatol; 2024 Jan; 33(1):e15003. PubMed ID: 38284189
[TBL] [Abstract][Full Text] [Related]
6. A Prospective, Monocentric Case-Control Study on Uncontrolled Psoriasis as Independent Risk Factor for a Hypercoagulable State.
Hillary TM; Vanhoutvin T; Peeters M; Imbrechts M; Vanassche T; Garmyn M; Vermeire S
Dermatol Ther (Heidelb); 2024 Mar; 14(3):767-775. PubMed ID: 38451420
[TBL] [Abstract][Full Text] [Related]
7. Association of serum IL-30 and soluble GP130 with the risk of psoriasis vulgaris.
Shehata RR; Atta SA; Fatma AS; Aml RA; Gomaa AS
Egypt J Immunol; 2024 Apr; 31(2):61-70. PubMed ID: 38615236
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non-responders: Subgroup analysis of UNCOVER-3 trial.
Rosmarin D; Smith S; Shrom D; Burge R; See K; McKean-Matthews M; Ridenour T; Lin CY; Gorelick J
Skin Health Dis; 2021 Sep; 1(3):e43. PubMed ID: 35663140
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-125a-5p regulates the effect of Tregs on Th1 and Th17 through targeting ETS-1/STAT3 in psoriasis.
Yan K; Zhang F; Ren J; Huang Q; Yawalkar N; Han L
J Transl Med; 2023 Sep; 21(1):678. PubMed ID: 37773129
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in Juvenile Idiopathic Arthritis: State of the Art and Future Perspectives.
Pelassa S; Raggi F; Rossi C; Bosco MC
Biology (Basel); 2023 Jul; 12(7):. PubMed ID: 37508421
[TBL] [Abstract][Full Text] [Related]
11. Pharmaco-Omics in Psoriasis: Paving the Way towards Personalized Medicine.
Antonatos C; Asmenoudi P; Panoutsopoulou M; Vasilopoulos Y
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108251
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in Several Cutaneous Autoimmune Diseases: Psoriasis, Cutaneous Lupus Erythematosus and Atopic Dermatitis.
Domingo S; Solé C; Moliné T; Ferrer B; Cortés-Hernández J
Cells; 2020 Dec; 9(12):. PubMed ID: 33321931
[TBL] [Abstract][Full Text] [Related]
13. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
[TBL] [Abstract][Full Text] [Related]
14. Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients.
Jin W; Zhang S; Duan Y
Dermatology; 2019; 235(1):55-64. PubMed ID: 30408786
[TBL] [Abstract][Full Text] [Related]
15. Plasma miR-126 expression correlates with risk and severity of psoriasis and its high level at baseline predicts worse response to Tripterygium wilfordii Hook F in combination with acitretin.
Duan Y; Zou J; Mao J; Guo D; Wu M; Xu N; Zhou J; Zhang Y; Guo W; Jin W
Biomed Pharmacother; 2019 Jul; 115():108761. PubMed ID: 31100542
[TBL] [Abstract][Full Text] [Related]
16. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis.
Reich K; Sinclair R; Roberts G; Griffiths CE; Tabberer M; Barker J
Curr Med Res Opin; 2008 May; 24(5):1237-54. PubMed ID: 18355421
[TBL] [Abstract][Full Text] [Related]
18. Measurement of circulating miRNA-125a exhibits good value in the management of etanercept-treated psoriatic patients.
Pei D; Cao J; Qin G; Wang X
J Dermatol; 2020 Feb; 47(2):140-146. PubMed ID: 31820498
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
